Adaptive Biotechnologies to Report Third Quarter of 2022 Financial Results on November 3, 2022

Rhea-AI Summary

Adaptive Biotechnologies (Nasdaq: ADPT) will announce its third-quarter 2022 financial results after market close on November 3, 2022. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, which will be available via live webcast on the company’s website. The company focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating diseases, including cancer and autoimmune disorders. Its proprietary platform is designed to decode the complexities of the immune system, enabling innovative diagnostics and therapeutics.

SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that translates the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2022 after market close on Thursday, November 3, 2022. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies
Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS
Karina Calzadilla, Vice President, Investor Relations
201-396-1687
Carrie Mendivil, Gilmartin Group
investors@adaptivebiotech.com

ADAPTIVE MEDIA
Laura Cooper
205-908-5603
media@adaptivebiotech.com

FAQ

When will Adaptive Biotechnologies report its third-quarter 2022 results?

Adaptive Biotechnologies will report its third-quarter 2022 financial results on November 3, 2022.

What time is the conference call for the third-quarter 2022 results?

The conference call will take place at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

How can I access the webcast for Adaptive Biotechnologies' financial results?

The webcast can be accessed through the 'Investors' section of the Adaptive Biotechnologies website.

What is the focus of Adaptive Biotechnologies?

Adaptive Biotechnologies focuses on harnessing the adaptive immune system to develop diagnostics and treatments for diseases.

What diseases are targeted by Adaptive Biotechnologies' products?

Adaptive Biotechnologies develops products for diagnosing and treating diseases such as cancer, autoimmune disorders, and infectious diseases.